Immunotherapy for colon cancer (multiple letters) [2]

Lancet

Volumn 353, Issue 9163, 1999, Pages 1524-1526

  Blot, E ^a   Delastre, O ^a   Levesque, H ^a   Bremers, A J A ^a   Parmiani, G ^a   Vermorken, J B ^a   Claessen, A M E ^a   Van Tinteren, H ^a   Hanna, M G ^a   Pinedo, H M ^a   Lukacs, K V ^a   Davies, M G ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; HUMAN; IMMUNOTHERAPY; LETTER; METHODOLOGY; PRIORITY JOURNAL; TREATMENT OUTCOME; ACTIVE IMMUNIZATION; CAUSE OF DEATH; COLON TUMOR; EPIDEMIOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; NOTE; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

BIAS (EPIDEMIOLOGY); CAUSE OF DEATH; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS;

EID: 0033132303     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)75133-3     Document Type: Letter

References (2)

1. JB Vermorken AME Claessen H van Tinteren Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial Lancet 353 1999 345 350
2. R Migdley D Kerr Colorectal cancer Lancet 353 1999 391 399